Just some further insight on to where and what this end product is looking at, with market and price...
as mentioned above, all Diabetics are at risk of developing CKD (Chronic Kidney Disease) and Hyperkalemia (high potassium blood levels) and therefore further serious health complications including total kidney failure and heart problems and ultimately death. This is serious business ..
if we were to correlate the CGM market with the twin CKD market, then we can look at the industry figures and projected growth for the CGM's to get an idea of our Lab on Chip end product value.
Cheers, Fish.
Just some further insight on to where and what this end product...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
26.0¢ |
Change
-0.010(3.70%) |
Mkt cap ! $66.26M | |||
| Open | High | Low | Value | Volume |
| 27.0¢ | 27.0¢ | 26.0¢ | $49.73K | 186.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 190211 | 26.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.5¢ | 157440 | 1 |
View Market Depth
| Last trade - 16.10pm 18/06/2025 (20 minute delay) ? |
| AXE (ASX) Chart |